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OBJECTIVE — Type 2 diabetes is associated with insulin resistance and skeletal muscle
mitochondrial dysfunction. We have found that subjects with early-onset type 2 diabetes show
incapacity to increase VO2max in response to chronic exercise. This suggests a defect in muscle
mitochondrial response to exercise. Here, we have explored the nature of the mechanisms
involved.
RESEARCH DESIGN AND METHODS — Muscle biopsies were collected from young
type 2 diabetic subjects and obese control subjects before and after acute or chronic exercise
protocols, and the expression of genes and/or proteins relevant to mitochondrial function was
measured. In particular, the regulatory pathway peroxisome proliferator–activated receptor 
coactivator (PGC)-1/mitofusin-2 (Mfn2) was analyzed.
RESULTS — At baseline, subjects with diabetes showed reduced expression (by 26%) of the
mitochondrialfusionproteinMfn2anda39%reductionofthe-subunitofATPsynthase.Porin
expression was unchanged, consistent with normal mitochondrial mass. Chronic exercise led to
a 2.8-fold increase in Mfn2, as well as increases in porin, and the -subunit of ATP synthase in
muscle from control subjects. However, Mfn2 was unchanged after chronic exercise in individ-
uals with diabetes, whereas porin and -subunit of ATP synthase were increased. Acute exercise
caused a fourfold increase in PGC-1 expression in muscle from control subjects but not in
subjects with diabetes.
CONCLUSIONS — Our results demonstrate alterations in the regulatory pathway that con-
trols PGC-1 expression and induction of Mfn2 in muscle from patients with early-onset type 2
diabetes. Patients with early-onset type 2 diabetes display abnormalities in the exercise-
dependent pathway that regulates the expression of PGC-1 and Mfn2.
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E
arly-onset type 2 diabetes is increas-
inginprevalence,inparallelwiththe
worldwideobesityepidemic(1),and
is typically characterized by early-onset
obesity and severe insulin resistance in
young people with a strong family history
oftype2diabetes(1,2).Weightreduction
and increased physical exercise are effec-
tive treatments to improve insulin sensi-
tivity. We have been studying the effects
of a variety of exercise and dietary regi-
mens in these very insulin-resistant pa-
tients. We recently demonstrated that a
3-month, four times weekly, aerobic ex-
ercise intervention in subjects with early-
onset type 2 diabetes failed to improve
VO2max and had no signiﬁcant effect on
whole-body or hepatic insulin sensitivity
(3). Equally obese nondiabetic control
subjects had a 20% increase in VO2max
following the same regime. This sug-
gested the possibility that, in these dia-
betic patients, chronic exercise training
failed to activate a mitochondrial oxida-
tive response.
Defective mitochondrial function in
skeletal muscle has been reported in a va-
riety of insulin-resistant states, including
type 2 diabetes (4,5). Muscle mitochon-
dria from type 2 diabetic subjects show
reduced size and reduced activity of the
electron transport chain (4,6). In parallel,
type 2 diabetes is associated with reduced
expression of genes of oxidative metabo-
lism as well as repression of the mito-
fusin-2 (Mfn2) gene, which encodes the
mitochondrial fusion protein mitofusin-2
(7–9). Decreased expression of nuclear
genes encoding proteins of oxidative
phosphorylation has been reported in
skeletalmuscleofnondiabeticindividuals
with a family history of type 2 diabetes
(8,9), along with reduced in vivo oxida-
tive phosphorylation (5). These ﬁndings
suggest that mitochondrial abnormalities
in type 2 diabetes may have a heritable
component.
Chronic exercise induces mitochon-
drialbiogenesisinskeletalmuscleanden-
hances mitochondrial function (10).
Exercise is known to induce PGC-1
(11), which in turn induces the transcrip-
tion of different nuclear genes encoding
mitochondrial proteins (12,13). One ex-
ample is Mfn2, which is induced by
PGC-1 through interaction with the
transcription factor ERR (14). This may
be particularly relevant, since it has been
reported that Mfn2 regulates not just mi-
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function through changes in mitochon-
drial membrane potential and the expres-
sion of OXPHOS subunits (15). The
stimulatory effect of exercise on mitochon-
drial biogenesis and function has also been
reported in muscle in insulin-resistant con-
ditions such as obesity (6) and aging (16)
and in type 2 diabetes (17).
Subjects who took part in the chronic
exercise protocol (3) underwent skeletal
muscle biopsies at baseline and after 3
months of exercise training. To address
mechanistic questions, we measured the
expression of mitochondrial proteins
from this initial study. We then con-
ducted an acute (short-term) exercise in-
tervention protocol in a similar cohort of
patients with early-onset type 2 diabetes
and examined the expression in muscle
biopsies of a range of speciﬁc mitochon-
drial genes and proteins. We hypothe-
sized that the lack of a whole-body
response to exercise training in the early-
onset type 2 diabetic subjects may be a
consequence of alterations in the abun-
dance or activity of relevant mitochon-
drial proteins in skeletal muscle.
RESEARCH DESIGN AND
METHODS— Subjects with early-
onset type 2 diabetes (i.e., diagnosed be-
fore age 25 years and negative for GAD
antibodies) were recruited from our
clinic, along with obese and otherwise
healthy subjects who were as far as possible
matched for age and BMI, but with normal
glucose tolerance and without family his-
toryofdiabetes.Allsubjectsweresedentary.
All gave written informed consent for the
study, which had been approved by the lo-
cal research ethics committee.
Clinical and metabolic characteristics
of both groups of subjects, in each study,
are summarized in Tables 1 and 2.
Concurrent medications
None of the obese control subjects was
receiving medications during the course
of these studies.
Chronic exercise study. All subjects
were receiving metformin. One subject
wasalsoreceivinggliclazide.Dosesoforal
hypoglycemic agents were unchanged
during the course of the study.
Acute exercise study. Three subjects
wereondietarymanagementalone.Seven
of the 12 subjects were receiving oral hy-
poglycemic agents alone. Two subjects
were on oral and insulin combination
therapy (metformin plus basal bolus
insulin treatment). All subjects on oral
hypoglycemic agents were on stable
doses throughout the duration of the
study. Subjects on the combination
therapy had their insulin doses reduced
by 20% during the course of the
study.
Baseline studies
Baseline studies were identical for both
the chronic and acute exercise studies (3)
and included the following.
Screening. Each subject was screened
withamedicalhistoryandphysicalexam-
ination and routine blood and urine bio-
chemistries. Waist-to-hip ratio, weight,
height, and BMI were measured. Blood
pressure was measured using the left arm
afterthesubjecthadbeensittingcomfort-
ably for 5 min, using an oscillometric de-
vice (Omron 705 CP). Three readings
were taken and the lowest one recorded.
Body composition was assessed using an
electrical impedance device (Tanita Body
Composition Analyzer). An exercise
stress test with electrocardiogram and ox-
ygen uptake was performed. Subjects
with any abnormal stress response were
excluded, as were those with clinically
signiﬁcant abnormalities on routine lab
testing.
Aerobic capacity (VO2peak). Maximal
oxygen consumption was measured by
treadmill, as previously described (3).
Muscle biopsy. Muscle biopsies were
taken either after an overnight fast or im-
mediately after the most recent session of
exercise, as described below.
Biopsies were obtained under local
anesthesia from the vastus lateralis mus-
cle. The muscle samples were immedi-
ately frozen in liquid nitrogen and stored
for protein extraction for samples from
pre- and 12 weeks post-exercise program
(chronic exercise study) and subse-
quently for both RNA and protein extrac-
tion (acute exercise study: for samples
pre- and 1-h and 7 days post-exercise).
Hyperinsulinemic-euglycemic clamp.
A clamp study (with insulin infusion 40
mU   m
2   min
1) was performed at
baseline and after exercise training in the
chronic exercise study (3). Subjects tak-
ing insulin omitted the basal dose on the
nightbeforetheclampaswellasthedoseon
the morning of the clamp study. The glu-
cosedisposalrate(between80and120min
after commencement of the insulin infu-
sion) was calculated after correction for re-
sidualhepaticglucoseproductionusingthe
[6,6-
2H2] glucose tracer.
Table 1—Baseline characteristics of subjects in the chronic exercise study
Control subjects
Youth with type 2
diabetes
n 67
Male:female ratio 0:6 5:2
Age (years) 22  12 7  1*
Duration of diabetes (years) NA 3.2  1.5
Treatment for diabetes NA Met 7; Met/SU 1
Weight (kg) 108.7  10.6 108.1  6.7
BMI (kg/m
2) 37.78  3.43 33.23  1.81
Systolic blood pressure (mmHg) 104  3 122  5*
Diastolic blood pressure (mmHg) 71  37 2  3
Waist circumference (cm) 113.2  4.6 117.4  3.2
Waist-to-hip ratio 0.91  0.03 1.00  0.09
A1C (%) 5.5  0.2 8.2  0.6†
Fasting glucose (mmol/) 5.2  0.2 9.1  0.8†
Fasting insulin (pmol/l) 91.1  9.4 77.1  12.3
Fasting C-peptide (g/l) 3.4  0.3 3.1  0.4
Total cholesterol (mmol/l) 4.33  0.21 4.50  0.42
HDL (mmol/) 1.11  0.08 0.88  0.03*
LDL (mmol/l) 2.57  0.23 2.34  0.35
Triglycerides (mmol/l) 1.41  0.27 3.05  0.64*
Free fatty acids (mmol/l) 0.635  0.053 0.820  0.104
Glucose disposal (mol/min/kg/mU/l) 26.25  4.66 16.13  4.16
Vo2max (ml   kg
1   min
1) 28.61  1.94 22.67  1.57*
Data are means  SE, unless speciﬁed otherwise. *Signiﬁcantly different from control group (P  0.05).
†Signiﬁcantly different from control group (P  0.01). Met, metformin; SU, sulfonylurea.
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For more information on exercise train-
ing, see supplementary Figs. 1 and 2 in
the online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1305/DC1. The subjects maintained a sta-
ble diet and treatment for diabetes during
both exercise programs. Subjects exer-
cised either on a treadmill or a stationary
bicycle ergometer. Each session lasted for a
total of 70 min (5-min warm-up, 60-min
exercise, 5-min cool down) and was fully
supervised by an exercise physiologist or
physician. Each exercise session was con-
ducted at the same intensity, i.e., at 70% of
the subject’s VO2max. This intensity of exer-
cise has previously been shown by us and
others to improve insulin sensitivity in
obese middle-aged subjects with type 2 di-
abetes. Blood glucose was checked before
exercise, and heart rate and blood pressure
weremonitoredthroughoutexercise.Com-
pliance with the exercise regimens was
greater than 90%.
Chronicexercise. Aftercompletionofall
baselinemeasurementsandabaselinemus-
cle biopsy, subjects exercised for 4 1-h ses-
sions each week. Each exercise session was
conducted at 70% of the subject’s VO2max.
Thestudycontinuedforatotalof12weeks.
Baselinemeasurementswererepeatedanda
ﬁnal muscle biopsy was taken immediately
after the last exercise session at the end of
the study (3) (supplementary Fig. 1).
Acute exercise. After completion of all
baseline measurements and a baseline
muscle biopsy, subjects exercised for a
single 1-h session at 70% of VO2max.A
second muscle biopsy was taken immedi-
atelyaftertheﬁrstsessionofexercise.The
subjects then exercised for 1 h daily for 7
days, followed by a ﬁnal muscle biopsy
immediately after the ﬁnal exercise ses-
sion at the end of this study (supplemen-
tary Fig. 2).
RNA extraction and real-time quantita-
tive PCR (acute exercise study). For
more information on the RNA extraction
and real-time quantitative PCR, see the
online appendix.
Homogenate extracts from muscle bi-
opsies and Western blot assays (acute
and chronic exercise studies). Protein
homogenate was extracted from 25 mg
skeletal muscle. The muscle was im-
mersed in ice-cold medium buffer A (0.1
mM KCL, 5 mm MgCl2, 5 mm EGTA, 5
mm sodium pyrophosphate, pH adjusted
to 7.4, 2 m leupeptin, 2 m pepstatin,
0.5 mm phenylmethylsulphonylﬂuoride
for 2  10 min). After this, the muscle
was ﬁnely minced in 1/10 (wt/vol) buffer
B(0.25mMsacharose,50mmKCl,5mm
EDTA, 1 mm sodium pyrophosphate, 5
mm MgCl2, pH adjusted to 6.8, 2 m leu-
peptin, 2 m pepstatin, 0.5 mm phenyl-
methylsulphonylﬂuoride) and then
disrupted with a motor-driven Teﬂon/glass
homogenizer. The entire procedure was
performed at 0–4°C. The protein concen-
tration was determined using a Micro BCA
protein assay (Pierce, Rockford, IL). West-
ern blot assays were performed as reported
(15) (see online appendix).
Statistical analysis
Unpairedttestswereperformedtocompare
muscle protein expression between control
subjects and subjects with diabetes at base-
line (Fig. 1A). Paired ttests were performed
to compare the effects of chronic exercise
(Fig.1B)andacuteexercise(Fig.1C)onthe
expressionofarangeofproteinsandRNAs.
In all cases, signiﬁcance level for the t tests
was set at P  0.05.
RESULTS
Clinical and metabolic
measurements
Chronic exercise study. Baseline char-
acteristics (Table 1) of the chronic exer-
cise participants have been described
previously (3). The nondiabetic control
subjects were matched for BMI with the
diabetic group, but the diabetic subjects
were slightly older. The 3-month exercise
training program led to no signiﬁcant
change in whole-body or hepatic insulin
sensitivityineitherthecontrolsubjectsor
the subjects with diabetes (3). VO2max in-
creased by 20% in the control group
(from 28.61  1.94 to 35.15  2.95 ml  
kg
1   min
1, P  0.01), but was un-
changed in the group with diabetes
(22.67 1.57 vs. 24.40 1.50 ml  kg
1 
min
1, P 	 NS) after exercise. Fasting
plasmafreefattyacidconcentrationstended
to be lower at baseline, although not
reaching signiﬁcance, in the control
group(0.635vs.0.820mmol/l,P 	 NS)
and were signiﬁcantly lower (0.561 vs.
0.826mmol/l,P 	 0.003)inthecontrol
subjects after the 3-month exercise in-
tervention (3). No correlation was found
between either age or sex and VO2max (data
not shown).
Acute exercise study. The acute exer-
cise participants (Table 2) had a similar
phenotype to individuals we have re-
ported from previous studies (2,3). The
control subjects were matched for age
and BMI and had similar VO2max at
baseline to individuals with diabetes
(22.85  2.71 vs. 23.79  1.79 ml  
kg
1   min
1, respectively; P 	 NS).
Table 2—Baseline characteristics of subjects in the acute exercise study
Control subjects
Youth with type 2
diabetes
n 71 2
Male:female ratio 2:5 10:2
Age (years) 26  22 7  1
Duration of diabetes (years) NA 2.5  0.7
Treatment for diabetes NA Met 9; Met/Ins 2; Diet 3
Weight (kg) 113.9  11.2 114.5  7.3
BMI (kg/m
2) 39.13  2.54 36.13  1.78
Systolic blood pressure (mmHg) 117  3 127  4
Diastolic blood pressure (mmHg) 75  48 1  3
Waist circumference (cm) 120.2  6.1 111.4  4.8
Waist-to-hip ratio 0.98  0.03 0.99  0.02
A1C (%) 5.6  0.1 7.5  0.5†
Fasting glucose (mmol/l) 5.2  0.1 8.0  0.7†
Fasting insulin (pmol/l) 163.0  65.3 169.6  61.7
Fasting C-peptide (g/l) 5.3  1.2 3.4  0.4*
Total cholesterol (mmol/l) 4.13  0.32 4.29  0.26
HDL (mmol/l) 1.30  0.17 0.95  0.05*
LDL (mmol/l) 2.21  0.29 2.63  0.28
Triglycerides (mmol/l) 1.35  0.20 1.76  0.26
Free fatty acids (mmol/l) 0.67  0.16 0.77  0.22
Vo2max (ml   kg
1   min
1) 22.85  2.71 23.79  1.79
Data are means  SE, unless speciﬁed otherwise. *Signiﬁcantly different from control group (P  0.05).
†Signiﬁcantly different from control group (P  0.01). Ins, insulin; Met, metformin.
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were re-measured at the end of this pro-
tocol, since neither of these parameters
wereexpectedtochangeafteronly1week
of exercise training.
Expression of skeletal muscle
mitochondrial proteins at baseline
(combined baseline data from the
chronic and acute studies)
Muscle biopsies were collected from
young type 2 diabetes or control sub-
jects, homogenates were obtained and
the expression of mitochondrial pro-
teinswasstudied.Theyieldoftotalpro-
teins was similar in homogenates from
control and young type 2 diabetic sub-
jects (54.1  2.6 and 54.8  3.1 mg
protein/g of tissue in control and young
type 2 diabetic groups, respectively).
The young type 2 diabetic group
showed a reduced expression of the mi-
tochondrial fusion protein, Mfn2 (26%
reduction in those with diabetes) and
the alpha subunit of ATP synthase
(ATP5a1) (39% reduction in those with
diabetes) (Fig. 1A). Under these condi-
tions, the abundance of porin (a marker
of mitochondrial mass) and of the p37
subunit of Complex I of the respiratory
chain (Ndufa9) was unaltered indicat-
ing that the changes of Mfn2 and ATP
synthase were not secondary to changes
in mitochondrial mass (Fig. 1A).
Expression of skeletal muscle
mitochondrial proteins after 3 months
exercise: chronic exercise study
iChronic exercise was associated with the
induction of Mfn2 (2.8-fold increase),
porin (1.6-fold increase), and p37 sub-
unit of Complex I (Ndufa9) (1.7-fold
ncrease) in skeletal muscle from control
subjects (Fig. 1B). In the young type 2
diabetic group, chronic exercise caused a
different pattern of muscle changes. The
expressionofMfn2wasunchanged,while
there was induction in both Ndufa9 (2.0-
foldincrease)andporin(1.6-foldincrease
but not reaching statistical signiﬁcance)
(Fig. 1B).
Mitochondrial gene expression in
skeletal muscle in response to acute
exercise: acute exercise study
Muscle samples taken after 7 days of ex-
ercise showed no signiﬁcant changes in
gene expression (data not shown). How-
ever,acuteexerciseafter1hcausedasub-
stantial induction in PGC-1 gene
Figure 1—A: Baseline: Young type 2 diabetic subjects show an im-
pairedexpressionofmitochondrialproteinsinskeletalmuscle.Western
blot assays were performed in extracts obtained from skeletal muscle
biopsiesfrom11normalglucosetolerant(control)and16youngtype2
diabetic patients (young T2D). Data are means  SE. *Statistically
signiﬁcant difference compared with the control group at P  0.05.
Representative autoradiograms are also shown. B: Chronic exercise.
Chronic exercise causes a deﬁcient induction of muscle mitochondrial
proteins in young type 2 diabetic subjects. Western blot assays were
performed in extracts obtained from skeletal muscle biopsies from nor-
malglucosetolerantandyoungtype2diabeticpatientsbeforeandafter
a protocol of chronic exercise. Representative autoradiograms are
shown in the lower right corner. Data are means  SE. *Statistical
signiﬁcantdifferencecomparedwithbasalvaluesatP0.05.C:Acute
exercise. Acute exercise induces skeletal muscle PGC-1 gene expres-
sion in control but not in young type 2 diabetic subjects. Real-time PCR
was performed in skeletal muscle biopsies from nine normal glucose
tolerantandsixyoungtype2diabeticpatientsbeforeandafteranacute
session of exercise. Data are means  SE. *Statistical signiﬁcant dif-
ference compared with basal values at P  0.05.
PGC-1/mitofusin-2 pathway in early type 2 diabetes
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trol subjects (fourfold induction) (Fig.
1C). These changes in PGC-1 had re-
verted to baseline after 7 days of exercise
(data not shown). Control subjects also
showed an increased ERR gene expres-
sion (2.2-fold increase), although this did
not reach statistical signiﬁcance and no
changes in the gene expression of PGC-
1
, porin, Mfn2, or the mitochondrial
gene COXIII (Fig. 1C). In contrast, acute
exercise led to no change in PGC-1 gene
expressioninskeletalmuscleintheyoung
type 2 group, and the expression of ERR
(23% reduction), Mfn2 (30% reduction),
or porin (23% reduction) was signiﬁ-
cantly reduced (Fig. 1C). No changes in
PGC-1
 or COXIII gene expression were
detectedinyoungtype2diabeticsubjects
(Fig. 1C). We analyzed whether AMPK
was stimulated under these conditions;
however, we detected no phosphoryla-
tion of AMPK in either the control or type
2 diabetic subjects (data not shown). No
correlation was found between VO2max
and the expression of mitochondrial
genes or proteins (data not shown).
CONCLUSIONS — We have previ-
ously reported that young subjects with
type 2 diabetes are severely insulin resis-
tant, achieving a maximal glucose dis-
posal rate of only 2.15  0.42 mg   kg
1  
min
1, compared with 4.09  0.58 mg  
kg
1   min
1 in very obese control sub-
jects (3). We undertook the current stud-
ies to directly analyze a range of
parameters of muscle mitochondrial
function in these subjects at baseline and
after different durations of exercise train-
ing. The mitochondrial parameters reveal
interesting new abnormalities in the sub-
jects with diabetes both at baseline and
after exercise. At baseline, subjects with
diabetes display modestly (25%) re-
duced expression of Mfn2 and some
OXPHOS subunits. Thus, in the baseline
state, without any intervention, subjects
with diabetes showed a defective pattern
of mitochondrial protein expression in
muscle compared with equally obese
young people without diabetes. The pa-
tientswithtype2diabetes,incomparison
with matched obese control subjects,
weremarkedlydyslipidemic.Lipotoxicity
in the patients with diabetes at baseline
could either cause or result from the mi-
tochondrial abnormalities that we have
demonstrated in the current study.
After exercise, the mitochondrial
changeswehaveobservedaremuchmore
pronounced and are consistent with the
whole-body ﬁndings in these subjects.
Thus, in the obese nondiabetic subjects,
acuteexerciseinterventionwasassociated
with increased muscle expression of
genes encoding for PGC-1 and ERR
under conditions in which Mfn2 or porin
wasunchanged.Thesedataareconsistent
with prior observations indicating that
AMPK activity is stimulated by acute ex-
ercise in skeletal muscle in humans (18)
and that PGC-1 gene expression and
promoter activity are stimulated by
AMPK (19). Moreover, and based on the
observationsthatMfn2genetranscription
is induced by ERR, and coactivated by
PGC-1 (14), we propose that enhanced
PGC-1 activity will promote an increase
in Mfn2 gene transcription. In contrast
with this proﬁle, acute exercise caused a
reduction in the expression of genes en-
coding Mfn2 and porin in muscle from
the subjects with diabetes under condi-
tions in which PGC-1 remained un-
changed. These data can be explained by
the incapacity of acute exercise to stimu-
late AMPK activity in patients with diabe-
tes, which cancels the induction of
PGC-1 gene expression. We also pro-
pose that the reduced expression of the
Mfn2 gene (and perhaps the porin gene,
which also encodes for a mitochondrial
protein)maybeduetoreducedtranscrip-
tional activities of either PGC-1 or PGC-
1
, key regulators of Mfn2 transcription
(14,20). In the obese nondiabetic sub-
jects, chronic exercise training led to an
increase in both Mfn2 (2.8-fold) and
porin (1.6-fold), consistent with the in-
crease in VO2max observed after 3 months.
In subjects with diabetes, however, we
found no increase in Mfn2, consistent
with the lack of stimulation of whole-
body oxygen uptake. In spite of the lack
of induction of PGC-1 or Mfn2,
chronic exercise induced porin or
Ndufa9 expression in the type 2 dia-
beticsubjects.Theinductionofporinor
Ndufa9 in the absence of PGC-1 sug-
gests the existence of mechanisms of
mitochondrial biogenesis, alternative to
PGC-1 gene induction, that are trig-
gered by physical exercise.
Several studies have analyzed the ef-
fect of dietary and/or exercise interven-
tions aimed to promote weight loss in
obese or type 2 diabetic subjects. These
studies have detected that weight loss in-
duced by diet/exercise stimulate mito-
chondrial activity in skeletal muscle both
in obese subjects as well as in type 2 dia-
betic patients (17,21,22). In a recent
study, a delayed and reduced response in
PGC-1 expression was detected in mus-
cle from obese subjects in response to ex-
ercise (22). Under these conditions, the
expression of genes downstream of
PGC-1 such as NRF-1 or cytochrome c
oxidase subunit VIc also showed a re-
ducedresponseinobesesubjectsafterex-
ercise (22).
Interestingly, we have also noted a
markedly different response to bariatric
surgery in morbidly obese diabetic sub-
jects compared with a matched nondia-
betic cohort (23). Despite similar weight
loss(60kg)andamarkedimprovement
in insulin sensitivity in both groups, the
patients with diabetes showed a blunted
response in terms of glucose oxidation
and no signiﬁcant changes in the expres-
sion of Mfn2, porin, and citrate synthase
(23). In all, these data together with data
from our current study suggest a link be-
tween insulin resistance and a defective
regulation of PGC-1 and downstream
mitochondrial proteins in response to ex-
ercise, so that under conditions of severe
insulin resistance, the induction of
PGC-1 in response to exercise is abol-
ished. Further studies should investigate
whetherthedefectivePGC-1expression
isaprimarydefectorwhetheritissecond-
ary to insulin resistance or reversible
lipotoxicity.
There are further possible explana-
tionstolinkenvironmentaleffectssuchas
diet and physical activity with abnormal-
ities of mitochondrial oxidative proteins
in patients with type 2 diabetes. In a re-
cent muscle biopsy study in human sub-
jects including control subjects, subjects
withimpairedglucosetolerance,andsub-
jects with type 2 diabetes, it was shown
that type 2 diabetes is associated with hy-
permethylation of PGC-1, concomitant
withreducedmitochondrialcontent(24).
Epigenetic effects may also modulate the
effectofdietandactivityonthepathogen-
esis of diabetes and could explain at least
some of the abnormalities observed in the
current study.
We acknowledge some limitations
in the current studies. The overall num-
ber of subjects included is small, and it
was not possible with these numbers to
matchgroupsforsex.Early-onsettype2
diabetes remains uncommon, and it is
challenging to recruit young subjects of
working age for these relatively com-
plex protocols. In the initial (chronic
exercise) study, the skeletal muscle in-
vestigations were limited by the biopsy
amount, and it was not possible to mea-
sure PGC-1 or other gene expression.
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early-onset type 2 diabetes is associated,
at baseline, with reduced expression of
skeletal muscle Mfn2, which is associated
with concomitant reduction in activity of
certain oxidative phosphorylation sub-
units. In addition, subjects with early-
onset type 2 diabetes are characterized by
a deﬁcient capacity to induce PGC-1 or
Mfn2 in response to aerobic exercise
training. These alterations in Mfn2 ex-
pression and the failure to stimulate
PGC-1 may be relevant to the ob-
served incapacity in these patients to
enhance whole-body VO2max in re-
sponse to exercise training. Further
mechanistic studies of these pathways
in this patient group are clearly indi-
cated. A more complete understanding
of these mechanisms will be crucial to
the design of lifestyle interventions to
prevent and treat type 2 diabetes in ad-
olescents and young adults.
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